Objective To explore the efficacy and safety of metformin vs.rosiglitazone on type 2 diabetes mellitus patients by analyzing published RCTs with meta-analysis approach.Methods A comprehensive search of related RCTs was performed in several biomedical databases.We screened literatures in accordance with the inclusion and exclusion criteria and assessed the methodological quality of included studies.The meta-analysis was performed using RevMan 5.3 software.Results As compared with rosiglitazone, metformin significantly decreased the serum glycosylated hemoglobin(HbA1c)level more effectively.However,they were not significantly different in controlling fasting plasma glucose and fasting insulin level.On the other hand,metformin accounted for a higher risk of gastrointestinal complaints,but a lower risk of edema than rosiglita-zone.Conclusion Compared with rosiglitazone,metformin shows a better improvement on long-term glycemic control and a lower risk of edema.Comparison of safety of the two still needs further study.%目的 系统对比二甲双胍与罗格列酮治疗2型糖尿病的有效性和安全性.方法 全面检索常用生物医学数据库中有关二甲双胍与罗格列酮治疗2型糖尿病的随机对照试验,参照纳入与排除标准独立进行文献筛选及质量控制,采用RevMan 5.3版软件等进行Meta分析.结果 与罗格列酮相比,二甲双胍能更有效地降低糖化血红蛋白水平,但二者在控制空腹血糖和空腹胰岛素上并无显著差异.此外,服用二甲双胍更易引发胃肠道不良反应,而服用罗格列酮者发生水肿危险性更大.结论 与罗格列酮相比二甲双胍可更显著地改善糖化血红蛋白水平,且引起水肿的危险性更低.二者安全性对比尚需进一步论证.
展开▼
